Bioequivalence and Bioavailability Forum 12:23 UTC

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Ramesh Ramalingam
Junior

India,
2018-10-18 05:16

Posting: # 19463
Views: 225
 

 Theophylline ER 450 mg study design [Design Issues]

Dear Members,

Based on literature reference, Theophylline is a narrow therapeutic index drug. As per USFDA recommendation if the drugs falls under narrow therapeutic index, the BE study should be a fully replicated crossover design in order to:
• Scale bioequivalence limits to the variability of the reference product; and
• Compare test and reference products within-subject variability.

But respective molecule OGD (which was issued on 2010) Draft guidelines recommending two-way cross-over study design.

Could you please suggest the study design whether it should be two-period, two-way crossover design or four period, fully replicated design.


Regards,
Ramesh
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,881 posts in 4,026 threads, 1,271 registered users;
online 34 (0 registered, 34 guests [including 26 identified bots]).

Being ignorant is not so much a shame,
as being unwilling to learn.    Benjamin Franklin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed